<DOC>
	<DOCNO>NCT00638963</DOCNO>
	<brief_summary>The purpose study determine whether temozolomide use prophylaxis brain recurrence participant metastatic breast cancer .</brief_summary>
	<brief_title>Temozolomide Prophylaxis Against Brain Recurrence Participants With Metastatic Breast Cancer ( P05225 AM2 )</brief_title>
	<detailed_description>Breast cancer second common cause brain metastasis . Overall survival development brain metastasis tend poor ( 6-8 month ) . Over-expression Human Epidermal Growth Factor Receptor 2 ( HER-2/neu ) , negative estrogen receptor , young age diagnosis seem indicator high risk brain metastasis . Temozolomide may good candidate prophylactic chemotherapy ability cross blood-brain-barrier , achieve high concentration central nervous system ( CNS ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Diagnosis metastatic breast cancer . Participants must complete first line metastatic chemotherapy achieve complete partial response disease stability least 6 month first confirmation disease stabilization . No clinical sign brain progression . At least one follow 3 condition : HER2 +++ , Young age ( &lt; 50 year ) , and/or estrogen receptor ( ER ) /progesterone receptor ( PgR ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Life expectancy ≥3 month . Neutrophils ≥1.5 x 10^9/L , platelet ≥100 x 10^9/L , hemoglobin ≥9 g/dL , lymphocytes ≥1 x 10^9/L . Bilirubin level either normal &lt; 1.5 x ULN ( upper limit normal ) . AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) ≤2.5 x ULN ( ≤5 x ULN liver metastasis present ) . Serum creatine &lt; 1.5 x ULN . Effective contraception risk conception exists . Concurrent chronic systemic immune therapy indicate study protocol . Any investigational agent ( ) within 4 week prior entry . Participants complete 2nd , 3rd , 4th line metastatic chemotherapy participant active chemotherapy treatment . Clinically relevant coronary artery disease history myocardial infarction within last 12 month . Acute sub acute intestinal occlusion history inflammatory bowel disease . Known Grade 3 Grade 4 allergic reaction component treatment . Known drug abuse/alcohol abuse . Legal incapacity limit legal capacity . Medical psychological condition opinion investigator would permit participant complete study sign meaningful informed consent . Women pregnant breastfeeding . Any concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix ( participant previous malignancy without evidence disease ≥5 year allow enter trial ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>